Dr. Eva Schernhammer Photo

Eva Schernhammer, D.P.H., M.D.

Adjunct Professor of Epidemiology, Harvard T.H. Chan School of Public Health
Lecturer on Medicine, Part-time, Brigham and Women's Hospital
Harvard Titles

Adjunct Professor Epidemiology, Harvard T.H. Chan School of Public Health
Lecturer on Medicine, Part-time

Other Affiliations

Channing Division of Network Medicine, Brigham and Women's Hospital

Address

Channing Laboratory
181 Longwood Avenue, 4th Floor, Room 444
Boston, MA 02115

Publications View
Harvard launches a workshop series targeting the control of obesity in the U.S
Authors: Schernhammer ES
Cancer Causes & Control
Insulin-like growth factor and breast cancer risk: evidence from observational studies [invited review]
Authors: Hankinson SE, Schernhammer ES
Breast Diseases
Light at night: A novel risk factor for cancer in shift workers? [invited review]
Authors: Schernhammer ES, Hankinson SE
Clinics in Occupational and Environmental Medicine/ Chronobiology and Shiftwork
In-utero exposures and breast cancer risk: joint effect of estrogens and insulin-like growth factor?
Authors: Schernhammer ES.
Cancer Causes Control
View full abstract on Pubmed
Gallstones, cholecystectomy, and the risk for developing pancreatic cancer.
Authors: Schernhammer ES, Michaud DS, Leitzmann MF, Giovannucci E, Colditz GA, Fuchs CS.
Br J Cancer
View full abstract on Pubmed
Response: Night shift work, light at night, and risk of breast cancer [editorial]
Authors: Schernhammer ES, Colditz GA
J Natl Cancer Inst
Rotating night shifts and risk of breast cancer in women participating in the nurses' health study.
Authors: Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA.
J Natl Cancer Inst
View full abstract on Pubmed
First-line therapy in head and neck cancer with docetaxel/cisplatin
Authors: Baur M, Kienzer H, Schweiger J, DeSantis M, Poehnl R, Schernhammer E, Postner G, Kraus R, Pont J, Schratter-Sehn A, Wicke W, Dittrich CH
Ann Oncol (Pro ESMO, Athens, Greece)
Carboplatin/mitomycin C (MMC) as salvage therapy with intraindividual dose escalation in advanced breast cancer
Authors: Fazeny B, Stubenvoll R, DeSantis M, Poehnl R, Soucek B, Schernhammer E, Postner G, Kienzer H, Kraus R, Pont J, Dittrich CH
Pro ASCO, Los Angeles, CA
Docetaxel/cisplatin as first-line therapy in head and neck cancer
Authors: Kienzer H, Schweiger J, Baur M, DeSantis M, Poehnl R, Gerber E, Soucek B, Schernhammer E, Postner G, Pont J, Schlappack A, Schratter-Sehn A, Wicke W, Dittrich CH
Pro ASCO